David Schulte, DO
Internal Medicine · Grovetown, GANPI 1255680096
Payments from drug & device makers
Across 357 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$793
- GSK$564
- AbbVie$500
- AstraZeneca$360
- Boehringer Ingelheim$350
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,92399%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 125 | $1,854 |
| Lilly USA, LLC | 45 | $793 |
| GSK | 31 | $564 |
| AbbVie(2 entities) | 33 | $500 |
| AstraZeneca | 23 | $360 |
| Boehringer Ingelheim | 15 | $350 |
| Bayer | 12 | $235 |
| Pfizer | 8 | $162 |
| Merck | 8 | $143 |
| Lundbeck LLC | 6 | $121 |
| Novartis | 6 | $111 |
| Amgen | 7 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $98 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Boston Scientific | 1 | $56 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Johnson & Johnson | 2 | $40 |
| Genentech USA, Inc. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $27 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Abbott | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$125
- TRELEGY ELLIPTA$117
How this compares
$5,960 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 109 | $145,817 |
| JardianceEmpagliflozin | 111 | $133,254 |
| EliquisApixaban | 105 | $110,309 |
| OzempicSemaglutide | 48 | $92,770 |
| FarxigaDapagliflozin Propanediol | 76 | $66,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $66,133 |
| JanuviaSitagliptin Phosphate | 45 | $58,280 |
| RybelsusSemaglutide | 18 | $33,559 |
| XareltoRivaroxaban | 30 | $32,752 |
| EntrestoSacubitril/Valsartan | 22 | $29,478 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $21,011 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $11,170 |
| Repatha SureclickEvolocumab | 11 | $10,468 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $5,856 |
| Novolog FlexpenInsulin Aspart | 20 | $5,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $793 | $145,817109 claims |
| Boehringer IngelheimJardiance | $350 | $133,254111 claims |
| Novo NordiskOzempic, Rybelsus | $1,854 | $126,32966 claims |
| PfizerEliquis | $162 | $110,309105 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $564 | $92,999138 claims |
| AstraZenecaFarxiga | $360 | $66,78476 claims |
| MerckJanuvia | $143 | $58,28045 claims |
| Johnson & JohnsonXarelto | $40 | $32,75230 claims |
| NovartisEntresto | $111 | $29,47822 claims |
| AbbVieSynthroid | $500 | $4,35142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Grovetown
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.